The European Medicines Agency (EMA) released its 2013 budget earlier this month per a recent article published in  The budget includes a 4% increase on its expenditures and projects other potential funding sources (e.g. EU) will increase slightly compared to 2012. To compensate for the increase in spending, the EMA plans to increase drug maker fees, as well as what it charges for Orphan Drugs. Additionally, the agency announced that it will be undergoing reorganization in an attempt to increase efficiency. To read the full article from, click here.

Need help with an EMA regulatory submission?   Contact us at